Chimeric Antigen Receptor T-cell (CAR-T) therapy has established itself as one of the most disruptive innovations in modern medicine. Since the first approval in 2017, CAR-T therapies have transformed outcomes in hematologic malignancies, achieving deep, durable remissions in patient populations previously resistant to standard therapies. This clinical success has fueled interest in leveraging CAR-T’s precision and potency beyond oncology. Among emerging frontiers, autoimmune diseases represent a particularly compelling opportunity, where CAR-T offers the prospect of an immune system reset rather than symptomatic suppression.
From Oncology to Autoimmunity: A Platfo...
